Ir para o conteúdo

San Antonio Breast Cancer Symposium

@sabcs.bsky.social did:plc:noiqwwgdlh2wyc5m5shunks3

SABCS is the world's largest gathering of doctors, researchers and scientists sharing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy for breast cancer and premalignant breast diseases. www.sabcs.org

No Bluesky desde

Seguidores
1.223
Seguindo
6
Posts
161
Dias nos rankings
0

Resumo

San Antonio Breast Cancer Symposium (@sabcs.bsky.social) é um usuário do Bluesky desde 20 novembro 2024. Tem 1.223 seguidores, segue 6 contas e publicou 161 posts.

Aparições nos rankings

Os melhores dias em que posts desta conta entraram na lista diária do Debya.

Esta conta ainda não apareceu em um ranking diário.

Posts curtidos recentemente

Curtidas públicas da rede Bluesky.

  • Stacey Tinianov, MPH@coffeemommy.bsky.social

    Mid-week into hot-off-the-press research results at the annual @sabcs.bsky.social Grateful to be sharing space and hugs with fellow advocates and colleagues 💗 #SABCS25

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    @ncasasanta.bsky.social presents data at #SABCS25: In advanced #breastcancer, genomic profiling shows younger women more frequently have BRCA1/2, TP53, HRD, and PD-L1 alterations, while older women more often exhibit ESR1, PIK3CA, CDH1, and higher TMB. @sabcs.bsky.social @oncoalert.bsky.social

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    Dr. Guannan Gong shares how an #AI-driven patient-matching system improved ID of eligible patients for #breastcancer trials + increased representation of under-enrolled groups. #SABCS25 @maryamlustberg.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    New research from Dr. Lajos Pusztai #SABCS25 shows RNA levels of ESR1, PGR closely match traditional estrogen receptor/progesterone receptor test results in #breastcancer. @foundationmedicine.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    Dr. Mariya Rozenblit highlights how C1D15 DiviTum® TKa levels can uncover early adherence issues or drug interactions during CDK4/6 inhibitor therapy. #SABCS25 Takeaway: DiviTum® TKa is a practical early biomarker to optimize breast cancer treatment outcomes. @sabcs.bsky.social

    Ver post

Entre para ver mais

Contas que bloqueia

No Bluesky, bloqueios são registros públicos.

Esta conta não bloqueia ninguém.